At HLTH last week, Jessica Federer announced The Women's Health Fund, a fund of funds designed to activate $60 billion in life sciences assets under management for women's health investing.
The structure is interesting not because women's health needs more capital - though it does of course - but because of where in the stack that capital is needed.
Women's health has early-stage infrastructure now. Specialist funds exist. They've been writing seed and Series A checks. Companies are getting built. But those specialist funds are smaller - a few years ago, the largest was $40 million. Even now, with two $250 million funds announced this year, they're still too small to lead enough growth rounds.
The companies they've funded need Series B, Series C, Series D capital. And that's where the gap is.
The fund of funds structure isn't trying to add more early-stage capital. It's trying to activate the capital that can write $20M, $50M, $100M checks - established life sciences funds with the expertise and infrastructure to take companies through regulatory approval, clinical trials, and exits.
The bet is that those funds have the capability but haven't prioritized women's health as a category. Give them capital specifically earmarked for it, and they'll build portfolios.
How the Mechanism Works
A traditional fund raises capital and invests directly in companies. A fund of funds invests in other funds, who then invest in companies.
The Women's Health Fund (WH1) plans to invest in 15 top-performing life sciences funds with experienced managers. Those funds then deploy into women's health companies, likely at later stages where their expertise in scaling life sciences companies matters most.
This does a few things:
Borrows existing infrastructure. These aren't new funds learning the space. They already know how to take companies from Series A through exit. They have relationships with pharma, biotech, and device companies. They understand regulatory pathways. You're essentially buying into proven infrastructure and pointing it at women's health.
Outsources pipeline development. Each fund you invest in is doing sourcing and due diligence in their domain. Invest in 15 specialized funds, and you get 15 teams building deal flow. Much more efficient than building that capacity yourself.
Creates later-stage capital pool. This is the real unlock. Companies that raised seed or Series A from specialist funds now have access to growth capital from funds that can actually write the checks they need.
Enables potential co-investment. As the structure matures, The Women's Health Fund could evolve into a hybrid model - starting as pure fund of funds, then co-investing directly alongside portfolio funds in later rounds. You begin as infrastructure, you become an active player with privileged access to vetted opportunities.
What This Changes
For founders, the Series B+ gap starts closing. One of the persistent challenges in women's health has been that companies could raise early-stage capital but struggled to find growth investors. If established life sciences funds start building women's health portfolios, that changes. You're not just getting more capital - you're getting more experienced capital that knows how to scale life sciences companies.
The bar also rises. More competition for deals means companies need stronger science, clinical data, and commercial strategy.
For investors, this is a lower-risk entry point. If you want exposure to women's health but don't have deep category expertise, investing through experienced fund managers reduces risk. One investment gets you diversification across multiple funds, stages, and sub-sectors.
It also positions you for a structural shift. Sex-based differences in drug development are becoming standard practice, especially post-GLP-1 success. Getting exposure now means being early to that trend.
For the market, this is coordination infrastructure. Women's health investing has been fragmented - specialist funds doing early stage, scattered generalist funds doing one-off later-stage deals, no systematic approach. A fund of funds creates coordination: shared deal flow, collective learning about what works, relationships across the ecosystem.
The Risks
Fund of funds structures have inherent challenges:
Fee layers. You're paying fees to The Women's Health Fund and to the underlying funds. Returns need to justify that structure.
Coordination is operationally hard. Getting 15 different funds to actually build women's health portfolios and share learnings requires sustained effort and alignment.
The hybrid evolution isn't guaranteed. Moving from pure fund of funds to co-investment requires different capabilities - direct sourcing, due diligence, board seats, company-level value-add. Not all fund of funds make that transition successfully. They also don't necessarily have to.
Discipline if the category gets hot. Federer explicitly said they want "evidence-based sustainable growth," not the hype cycles that happened in cell and gene therapy or digital health. Maintaining that discipline gets harder if everyone suddenly wants in.
What to Watch
Whether the fund actually gets off the ground. Someone once told me that VC funds are like startups with different business models, and founding partners are like startup founders. Announcing a fund and actually raising it are two different things. This is a complex structure requiring coordination across multiple stakeholders - execution matters.
Which 15 funds get selected. This signals where The Women's Health Fund sees the strongest management teams and biggest opportunities - oncology, cardiovascular, neuroscience, reproductive health, diagnostics?
Whether a co-investment model emerges. If they start showing up directly in later-stage rounds, it means they're transitioning from pure infrastructure play to active investor.
How founders adapt. Do companies start explicitly positioning for funds in The Women's Health Fund's network? Does this change fundraising strategy?
Whether this model gets replicated. If it works, we might see similar structures in other underinvested categories.
What This Actually Represents
The fund of funds structure is a market-making mechanism. You're not waiting for women's health investing to mature organically - you're deliberately building infrastructure to accelerate it.
The insight is timing: early-stage infrastructure exists, companies are getting built, and now they need growth capital. But growth capital hasn't been systematically available. Activating $60 billion in existing life sciences assets solves that faster than waiting for more dedicated women's health funds to scale up.
The question isn't whether women's health is a good investment category - the economic case has been made, the science is catching up, and pharma is paying attention. The question is whether you can build the infrastructure fast enough to capture the opportunity.
A fund of funds is a bet that you can. Not by starting from scratch, but by activating what already exists.
If it works, women's health stops being a specialty category and becomes integrated into mainstream life sciences investing. And the companies that raised early-stage capital from specialist funds finally get access to the growth capital they need to scale.
That's the real test. Not whether the fund gets raised, but whether it actually unlocks the Series B+ market that's been missing.
